Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$1.91 USD
-0.17 (-8.17%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.90 -0.01 (-0.52%) 4:56 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.91 USD
-0.17 (-8.17%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $1.90 -0.01 (-0.52%) 4:56 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
Corcept (CORT) Thrives on Korlym Amid Overdependence Concerns
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Down 65% in 4 Weeks, Here's Why You Should You Buy the Dip in Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Verrica Pharmaceuticals Inc. (VRCA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 70.4% in 4 Weeks
by Zacks Equity Research
Verrica Pharmaceuticals Inc. (VRCA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Verrica (VRCA) Down 64% as Molluscum Drug Gets CRL From FDA
by Zacks Equity Research
Verrica Pharmaceuticals' (VRCA) new drug application for VP-102 to treat molluscum contagiosum faces rejection from the FDA for a second time.
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
by Zacks Equity Research
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
After Plunging 28.5% in 4 Weeks, Here's Why the Trend Might Reverse for Verrica Pharmaceuticals Inc. (VRCA)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's Why Verrica Pharmaceuticals Inc. (VRCA) is Poised for a Turnaround After Losing 31.6% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Verrica Pharmaceuticals Inc. (VRCA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Does Verrica Pharmaceuticals Inc. (VRCA) Have the Potential to Rally 60% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Verrica Pharmaceuticals Inc. (VRCA) points to a 59.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stock Roundup: Regulatory Updates From BIIB, BMY, EXEL, Setback for VRCA
by Ekta Bagri
Regulatory and pipeline updates from pharma giants like Biogen (BIIB) and Bristol Myers (BMY) have been some of the key highlights in the biotech sector during the past week.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed
by Zacks Equity Research
Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.
Verrica (VRCA) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study
by Zacks Equity Research
Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.
FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia
by Zacks Equity Research
FibroGen (FGEN) doses the first patient in a phase II study on roxadustat for the treatment of anemia in cancer patients receiving chemotherapy.
Will Verrica Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Verrica Pharmaceuticals.
FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins a marketing approval in Japan for treating anemia caused by chronic kidney disease in dialysis-dependent patients.
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Small Drug Stock Outlook: Innovation Holds the Key to Growth
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Verrica (VRCA) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Verrica (VRCA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.